ScinoPharm Taiwan: Leading API & CDMO Solutions

ScinoPharm Taiwan, established in 1997, stands as a premier pharmaceutical company renowned for its specialized work in high-barrier Active Pharmaceutical Ingredient (API) and drug product development and manufacturing. Located in the Tainan Science Park, ScinoPharm is a trusted strategic partner for global pharmaceutical clients, providing fully integrated solutions from initial API development to finished injectable drug products. The company combines advanced R&D with stringent manufacturing capabilities, particularly excelling in the oncology field. As a global Contract Development and Manufacturing Organization (CDMO) and API manufacturer, ScinoPharm collaborates with top-tier patented and generic pharmaceutical companies worldwide. They offer services that accelerate drug development processes and ensure quality throughout the product lifecycle. Their commitment extends beyond manufacturing to embracing sustainable practices and maintaining world-class quality and regulatory excellence. It is important to note that ScinoPharm Taiwan primarily operates as a business-to-business (B2B) entity within the pharmaceutical industry. The company's official website serves as a corporate platform, providing detailed information on its services, capabilities, and regulatory achievements. It does not feature a public-facing portal for individual patient login or management of personal health records.

Partnering with ScinoPharm: Collaboration Essentials

• Prospective partners engaging with ScinoPharm Taiwan should align with high standards of quality and regulatory compliance. The company is committed to patient safety and drug efficacy, with all products manufactured in full compliance with international cGMP standards, including PIC/S GMP, ICH Q10, FDA, EMA, and TFDA requirements.
• Collaborators can expect robust quality management frameworks, with ScinoPharm regularly undergoing audits by global health authorities and partners.
• For projects involving Active Pharmaceutical Ingredients (APIs) or Contract Development and Manufacturing Organization (CDMO) services, partners will benefit from ScinoPharm's expertise in high-potency APIs, small molecules, and peptides, alongside comprehensive analytical and regulatory support.

Connecting with ScinoPharm: B2B Interaction Points

1. ScinoPharm Taiwan's official website is a corporate information hub and does not offer a public login portal for individual users or patients to access personal accounts or health records. The company primarily operates in a business-to-business capacity, providing pharmaceutical development and manufacturing services to other companies.
2. For business partners, clients, and investors, communication and engagement are typically handled through direct contact channels, including dedicated customer service, investor relations, and corporate communications teams. Secure data exchange or project management systems for active collaborations would be established directly with relevant ScinoPharm departments.
3. Job seekers can explore opportunities and submit resumes via the careers section, often directing to platforms like 104 Job Bank or a dedicated HR email.

ScinoPharm's Comprehensive Pharmaceutical Offerings

• End-to-End API and Drug Product Solutions: ScinoPharm offers comprehensive services from API development and manufacturing to finished injectable solutions, acting as a one-stop provider.
• CDMO Expertise: With over 200 successful CDMO projects and extensive experience in peptide synthesis and API development, ScinoPharm delivers custom synthesis, process development, and analytical testing services.
• High-Potency API (HPAPI) Specialization: The company is a global leader in the supply chain of small-molecule APIs, specializing in high-potency active ingredients, particularly for oncology.
• Regulatory Excellence: ScinoPharm's facilities are FDA- and cGMP-compliant, consistently passing inspections by global regulatory authorities such as the FDA, EMA, PMDA, and ANVISA with zero-deficiency records.
• Advanced R&D Capabilities: They possess strong research and development capabilities in organic synthesis of small molecules and peptides, focusing on areas like oncology, CNS, and cardiovascular diseases.

Optimizing Projects: Addressing Client & Process Queries

Upholding Standards: Quality, Compliance & Information Safeguards

• 🔒 ScinoPharm Taiwan prioritizes patient safety and drug efficacy, adhering to rigorous quality systems that meet global cGMP, FDA, EMA, and PMDA standards. This commitment ensures the highest product quality and reliability.
• 🔒 The company integrates Quality Risk Management (QRM) and Quality by Design (QbD) principles throughout its operations, from early development to commercial manufacturing, to mitigate risks and ensure consistent quality.
• 🔒 ScinoPharm achieved ISO/IEC 27001:2022 Information Security Management System (ISMS) Certification in June 2026, demonstrating its dedication to protecting sensitive data and maintaining digital integrity.
• 🔒 As an Authorized Economic Operator (AEO), ScinoPharm meets global standards for supply chain security management and trade compliance, ensuring secure and reliable international trade practices.
• 🔒 Regular compliance inspections by global health authorities and internal audits ensure that ScinoPharm's operations consistently uphold world-class regulatory standards.

Insights into ScinoPharm Taiwan: Key Questions Answered